Related Experiment Video

Updated: Oct 22, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.5K

Efficacy and safety profile of avelumab monotherapy

Bin Zhao1, Meiling Gao1, Hong Zhao2

  • 1The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, 325027, China.

Critical Reviews in Oncology/Hematology
|August 30, 2021
PubMed

Insights

Avelumab monotherapy demonstrates significant anti-tumor activity and a favorable safety profile in cancer patients. This immunotherapy shows promising results, especially in PD-L1 positive individuals, supporting its expanded use in cancer treatment.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Avelumab is an antibody that targets cancer cells via immune checkpoint inhibition and antibody-dependent cell-mediated cytotoxicity (ADCC).
  • Understanding its clinical efficacy and safety profile is crucial for optimizing cancer treatment strategies.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of avelumab monotherapy across a large patient cohort.
  • To compare avelumab's outcomes against conventional treatments and analyze responses based on PD-L1 expression.

Main Methods:

  • A meta-analysis of 21 clinical trials involving 3935 cancer patients treated with avelumab monotherapy.
  • Data analysis focused on objective response rates (ORR), treatment-related adverse events (TRAEs), and immune-related adverse events (irAEs).

Main Results:

  • Avelumab monotherapy showed a pooled ORR of 14.18% (95% CI, 10.68%-18.08%), with higher response rates in PD-L1 positive patients.
  • The incidence of all-grade TRAEs was 73.78%, high-grade TRAEs was 14.44%, and all-grade irAEs was 17.86%.
  • Avelumab demonstrated comparable or improved tumor response and reduced adverse events compared to conventional treatments.

Conclusions:

  • Avelumab monotherapy exhibits active anti-tumor efficacy without increased toxicity, attributed to its mechanisms including ADCC.
  • These findings support the continued application of avelumab as a valuable option in cancer therapy.
Keywords:
AvelumabCheckpoint inhibitorsEfficacyImmunotherapySafetyToxicity profile

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.8K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.9K

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
32
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
556
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
771
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
34
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.2K